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According to WHO, tuberculosis (TB) is the leading cause of death from a single infectious 
organism worldwide and the number of cases with drug resistant TB is still increasing, creating 
the need for new antituberculotics. Therefore, we report design, synthesis and antimicrobial 
evaluation of a series of hybrid compounds combining different pyrazinamide derivates and p-
aminosalicylic acid as potential antituberculotic agents. The compounds were prepared by 
mixing different pyrazinecarboxylic acids, after activation by 1,1'-carbonyldiimidazole, with p-
aminosalicylic acid in dimethylsulfoxide as a solvent. Obtained compounds were in vitro tested 
for their antimycobacterial activity against M. tuberculosis H37Rv, M. tuberculosis H37Ra and 
four other mycobacterial strains. Prepared compounds were also in vitro screened for 
antibacterial, antifungal, and cytotoxic (HepG2) activity. Most compounds showed 
antimycobacterial activity in range of minimum inhibitory concentration (MIC) from 3.13–12.5 
µg/ml against M. tuberculosis H37Rv. The most active compound was 
4-(6-chloropyrazine-2-carboxamido)-2-hydroxybenzoic acid with MIC against M. tuberculosis 
H37Rv = 3.13 µg/ml (10,7 µmol.l-1). None of the prepared compounds exerted antibacterial, 
antifungal or cytotoxic activity. 
 
 
